SLC5A2 and type 2 diabetes mellitus: In humans, available data are limited to one retrospective study in men with uncontrolled type 2 diabetes, who received different combinations of antidiabetic regimens, including a subgroup of 16 patients who received metformin combined with the SGLT2 inhibitor dapagliflozin.